Abstract

Systems-level insights into inflammatory events after vascularized composite allotransplantation (VCA) are critical to the success of immunomodulatory strategies of these complex procedures. To date, the effects of tacrolimus (TAC) immunosuppression on inflammatory networks in VCA, such as in acute rejection (AR), have not been investigated. We used a systems biology approach to elucidate the effects of tacrolimus on dynamic networks and principal drivers of systemic inflammation in the context of dynamic tissue-specific immune responses following VCA. Lewis (LEW) rat recipients received orthotopic hind limb VCA from fully major histocompatibility complex-mismatched Brown Norway (BN) donors or matched LEW donors. Group 1 (syngeneic controls) received LEW limbs without TAC, and Group 2 (treatment group) received BN limbs with TAC. Time-dependent changes in 27 inflammatory mediators were analyzed in skin, muscle, and peripheral blood using Principal Component Analysis (PCA), Dynamic Bayesian Network (DyBN) inference, and Dynamic Network Analysis (DyNA) to define principal characteristics, central nodes, and putative feedback structures of systemic inflammation. Analyses were repeated on skin + muscle data to construct a “Virtual VCA”, and in skin + muscle + peripheral blood data to construct a “Virtual Animal.” PCA, DyBN, and DyNA results from individual tissues suggested important roles for leptin, VEGF, various chemokines, the NLRP3 inflammasome (IL-1β, IL-18), and IL-6 after TAC treatment. The chemokines MCP-1, MIP-1α; and IP-10 were associated with AR in controls. Statistical analysis suggested that 24/27 inflammatory mediators were altered significantly between control and TAC-treated rats in peripheral blood, skin, and/or muscle over time. “Virtual VCA” and “Virtual Animal” analyses implicated the skin as a key control point of dynamic inflammatory networks, whose connectivity/complexity over time exhibited a U-shaped trajectory and was mirrored in the systemic circulation. Our study defines the effects of TAC on complex spatiotemporal evolution of dynamic inflammation networks in VCA. We also demonstrate the potential utility of computational analyses to elucidate nonlinear, cross-tissue interactions. These approaches may help define precision medicine approaches to better personalize TAC immunosuppression in VCA recipients.

Highlights

  • The potential for vascularized composite allotransplantation (VCA) as a reconstructive or restorative option has been established in over 200 procedures performed worldwide, including 145 upper extremity, 42 face, and 26 uterus transplants

  • Skin and muscle biopsies at postoperative day (POD) 31 from Group 1 (Figure 1B) revealed no inflammatory infiltrates in epidermis or dermis [Figure 1B [1]] as well as in the muscle [Figure 1B [2]]

  • Vascular Endothelial Growth Factor (VEGF) was the sole central node in the muscle of Group 1 animals, with two-way connections to IFN-g and MCP1 along with various connections to multiple inflammatory mediators (Figure 2B, lower panel). These results suggest the possible role of tissue ischemia (VEGF) along with the leptin pathway

Read more

Summary

Introduction

The potential for vascularized composite allotransplantation (VCA) as a reconstructive or restorative option has been established in over 200 procedures performed worldwide, including 145 upper extremity (hand), 42 face, and 26 uterus transplants (with over 10 live births). The risks of lifelong, high-dose or multi-drug systemic immunosuppression remain the key challenge limiting life enhancing benefits of VCA [1,2,3]. Tacrolimus (TAC; FK506, Prograf ®), is an FDA-approved immunosuppressant which is the keystone agent in VCA protocols [4, 5]. TAC is mostly effective in controlling acute rejection (AR), it does not prevent chronic rejection (CR). The main limitation of TAC is its narrow therapeutic range, which underlies its toxic side effects [10,11,12]. Excessive immunosuppression with TAC can lead to nephrotoxicity, malignancy, or opportunistic infection); inadequate immunosuppression can increase risks of AR or CR

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call